Novo Nordisk Discloses Insider Share Transactions
Ticker: NONOF · Form: 6-K · Filed: Nov 17, 2025 · CIK: 353278
Sentiment: neutral
Topics: insider-trading, disclosure, regulation
TL;DR
Novo Nordisk insiders bought/sold shares on Nov 17, 2025, per market abuse rules.
AI Summary
On November 17, 2025, Novo Nordisk A/S disclosed transactions in its shares by board members, executives, and associated persons. This disclosure is in accordance with Article 19 of Regulation No. 596/2014 on market abuse, which governs reporting of insider trading.
Why It Matters
This filing provides transparency into the trading activities of company insiders, which can offer insights into their confidence in the company's future performance.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of insider trading activity and does not indicate any new material risks for the company.
Key Players & Entities
- NOVO NORDISK A S (company) — Registrant
- November 17, 2025 (date) — Date of disclosure
- Regulation No. 596/2014 (regulation) — Governing market abuse
FAQ
What type of transactions are being disclosed by Novo Nordisk's insiders?
The filing states that it discloses data of transactions made in Novo Nordisk shares by the company's board members, executives, and their associated persons.
What regulation governs these disclosures?
These disclosures are made in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
When was this company announcement made?
The company announcement was made on November 17, 2025.
Where is Novo Nordisk A/S headquartered?
Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
Is Novo Nordisk filing an annual report under Form 20-F or 40-F?
Novo Nordisk indicates it files annual reports under cover of Form 20-F.
Filing Stats: 515 words · 2 min read · ~2 pages · Grade level 13 · Accepted 2025-11-17 15:35:39
Filing Documents
- f6k_111725.htm (6-K) — 31KB
- logo.jpg (GRAPHIC) — 76KB
- ca.jpg (GRAPHIC) — 24KB
- 0001171843-25-007383.txt ( ) — 170KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized. Date: November 17, 2025 NOVO NORDISK A/S Maziar Mike Doustdar Chief Executive Officer